JNJ-6665
- Generic Name
- JNJ-6665
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 1
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsSolid Tumor, AdultMetastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06788509
- Locations
- π¨π³
Chang Kung Memorial Hospital, Kaohsiung City, Taiwan
π§πͺGhent University Hospital, Gent, Belgium
π«π·Hopital Claude Huriez, Lille, France
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 153
- Registration Number
- NCT04609826
- Locations
- π«π·
Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, France
π«π·CHU de Nice Hopital de l Archet, Nice, France
π«π·Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex 09, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath